Effects of JNJ-53718678 in Adult and Adolescent Participants Who Had a Hematopoietic Stem Cell Transplantation and Who Are Infected With Respiratory Syncytial Virus (RSV)
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Drug: JNJ-53718678 250 mgDrug: PlaceboDrug: JNJ-53718678 125 mg
- Registration Number
- NCT04056611
- Lead Sponsor
- Janssen Sciences Ireland UC
- Brief Summary
The purpose of this study is to evaluate the effect of JNJ-53718678 on the development of respiratory syncytial virus (RSV) lower respiratory tract infection (LRTIs) in adult hematopoietic stem cell transplant (HSCT) recipients with RSV upper RTI.
- Detailed Description
RSV is recognized as major respiratory pathogen in infants and young children and causes upper and lower respiratory illness among all age groups, often going undiagnosed. Immunocompromised (IC) participants have a reduced ability to combat infection due to an impaired or weakened immune system. Within the IC population, HSCT recipients are generally regarded as having a particularly high risk for more severe disease caused by RSV, representing a substantial unmet need for antiviral treatment of RSV infections in this participant population. JNJ-53718678 is an investigational, potent, small molecule, respiratory syncytial virus (RSV)-specific fusion inhibitor. The study will include a Screening Period (Day -2 to Day 1), a Treatment Period (Day 1 to Day 21), and a Follow-up Period (1 year). Assessments like chest X-ray, pulse/heart rate, respiratory rate, electrocardiogram (ECG), etc will be performed. Safety and efficacy will be assessed through the study. The total study duration for each participant will be approximately 49 days.
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 3
- Received an autologous or allogeneic hematopoietic stem cell transplant (HSCT) using any conditioning regimen
- Absolute lymphocyte count (ALC) less than (<) 1,000 cells/microliter (mL)
- Participant has laboratory confirmed RSV diagnosis within 48 hours of randomization
- New onset of at least 1 of the following respiratory symptoms within 4 days prior to the anticipated start of dosing nasal congestion, rhinorrhea, cough or pharyngitis (sore throat), and/or worsening of one of these chronic (associated with previously existing diagnosis, example, chronic rhinorrhea, seasonal allergies, chronic lung disease) respiratory symptoms within 4 days prior to the anticipated start of dosing
- Peripheral capillary oxygen saturation (SpO2) greater than or equal to (>=) 92 percent (%) on room air
- Admitted to the hospital primarily for a lower respiratory tract disease of any cause as determined by the investigator
- Requires supplemental oxygen at Screening or any time between Screening and randomization
- Documented to be positive for other respiratory viruses (limited to influenza, parainfluenza, human rhinovirus, adenovirus, human metapneumovirus, or coronavirus) within 7 days prior to or at the Screening visit, if determined by local SOC testing (additional testing is not required)
- Clinically significant bacteremia or fungemia within 7 days prior to or at Screening that has not been adequately treated, as determined by the investigator
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Adult cohort: JNJ-53718678 or Placebo JNJ-53718678 250 mg Participants greater than or equal to (\>=) 18 to less than or equal to (\<=) 75 years of age will receive 250 milligram (mg) JNJ-53718678 twice daily (bid) for 21 days (without coadministration with moderate or strong CYP3A4 inhibitors), or 125 mg JNJ-53718678 bid for 21 days (coadministered with moderate or strong CYP3A4 inhibitors with the exception of posaconazole), or 125 mg once daily (qd) for 21 days (when coadministered with posaconazole), or matching placebo for 21 days. Adult cohort: JNJ-53718678 or Placebo Placebo Participants greater than or equal to (\>=) 18 to less than or equal to (\<=) 75 years of age will receive 250 milligram (mg) JNJ-53718678 twice daily (bid) for 21 days (without coadministration with moderate or strong CYP3A4 inhibitors), or 125 mg JNJ-53718678 bid for 21 days (coadministered with moderate or strong CYP3A4 inhibitors with the exception of posaconazole), or 125 mg once daily (qd) for 21 days (when coadministered with posaconazole), or matching placebo for 21 days. Adult cohort: JNJ-53718678 or Placebo JNJ-53718678 125 mg Participants greater than or equal to (\>=) 18 to less than or equal to (\<=) 75 years of age will receive 250 milligram (mg) JNJ-53718678 twice daily (bid) for 21 days (without coadministration with moderate or strong CYP3A4 inhibitors), or 125 mg JNJ-53718678 bid for 21 days (coadministered with moderate or strong CYP3A4 inhibitors with the exception of posaconazole), or 125 mg once daily (qd) for 21 days (when coadministered with posaconazole), or matching placebo for 21 days. Adolescent cohort: JNJ-53718678 or Placebo Placebo Participants \>=13 to \<18 years of age will receive 250 mg JNJ-53718678 bid for 21 days (without coadministration with moderate or strong CYP3A4 inhibitors), or 125 mg JNJ-53718678 bid for 21 days (coadministered with moderate or strong CYP3A4 inhibitors with the exception of posaconazole), or 125 mg qd for 21 days (when coadministered with posaconazole), or matching placebo for 21 days. Adolescent cohort: JNJ-53718678 or Placebo JNJ-53718678 250 mg Participants \>=13 to \<18 years of age will receive 250 mg JNJ-53718678 bid for 21 days (without coadministration with moderate or strong CYP3A4 inhibitors), or 125 mg JNJ-53718678 bid for 21 days (coadministered with moderate or strong CYP3A4 inhibitors with the exception of posaconazole), or 125 mg qd for 21 days (when coadministered with posaconazole), or matching placebo for 21 days. Adolescent cohort: JNJ-53718678 or Placebo JNJ-53718678 125 mg Participants \>=13 to \<18 years of age will receive 250 mg JNJ-53718678 bid for 21 days (without coadministration with moderate or strong CYP3A4 inhibitors), or 125 mg JNJ-53718678 bid for 21 days (coadministered with moderate or strong CYP3A4 inhibitors with the exception of posaconazole), or 125 mg qd for 21 days (when coadministered with posaconazole), or matching placebo for 21 days.
- Primary Outcome Measures
Name Time Method Percentage of Participants Who Developed Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Infection (LRTI) Up to Day 28 Percentage of participants who developed RSV LRTI was assessed. RSV LRTI was defined as the development of a lower respiratory sign or symptom (including decrease in oxygen saturation or increase in supplemental oxygen to maintain oxygen saturation, wheezing, rhonchi, rales, dyspnea, tachypnea, worsening cough) and positive RSV test from lower respiratory tract sample (example \[eg\], sputum, induced sputum, bronchoalveolar lavage (BAL), lung biopsy, or autopsy specimen) within +-4 days of a new chest image finding, compared to baseline, consistent with a LRTI; OR positive RSV test from lower respiratory tract sample (eg, sputum, induced sputum, BAL, lung biopsy, or autopsy specimen) only; OR positive RSV test from upper respiratory tract sample within ±4 days of a new chest image finding, compared to baseline, consistent with a RSV LRTI as determined by the Endpoint Adjudication Committee (EAC).
- Secondary Outcome Measures
Name Time Method Percentage of Participants Who Developed RSV-associated Lower Respiratory Tract Complication (LRTC) Up to Day 28 Percentage of participants who developed RSV-associated LRTC was assessed. RSV-associated LRTC defined as development of lower respiratory sign/symptom (includes decrease in oxygen saturation/increase in supplemental oxygen to maintain oxygen saturation, wheezing, rhonchi, rales, dyspnea, tachypnea, and worsening cough) and met 1 of following subcategories determined by EAC: a) RSV LRTI, b) secondary bacterial LRTI (positive specimen for clinically significant bacterium within 4 days of new chest image finding, compared to baseline, consistent with LRTI), c) secondary LRTI due to unusual pathogens (positive specimen for clinically significant unusual organism within 4 days of new chest image finding, compared to baseline, consistent with LRTI), d) secondary LRTC of unknown etiology (new chest image finding than baseline, consistent with LRTI, inflammatory process/ some other clinically significant pulmonary process which were absent within 4 days of new chest image finding).
Number of Participants With Treatment-emergent Adverse Events (TEAEs) Up to Day 49 An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non investigational) product. An AE did not necessarily have a causal relationship with the intervention. Any AE which occurred post first dose administration of study drug up to the end of study (EOS) (that is, Day 49) was considered as treatment-emergent.
Percentage of Participants With Treatment-emergent Abnormal (>=Grade 3) Clinical Laboratory Findings Up to Day 49 Percentage of participants with greater than or equal to (\>=) Grade 3 treatment-emergent laboratory abnormalities (platelet count decreased, glucose increase) was assessed in this outcome measure. Treatment-emergent: any abnormality occurred post first dose of study drug up to end of study (that is, Day 49).
Percentage of Participants With Clinically Significant Abnormalities in Electrocardiogram (ECG) Findings Up to Day 49 Percentage of participants with clinically significant abnormalities in ECG findings was assessed in this outcome measure. Various ECG variables assessed were heart rate: abnormally low (\<= 45 beats per minute \[bpm\]), abnormally high (\>= 120 bpm); PR interval: abnormally high (\>=210 milliseconds \[msec\]); QRS interval: abnormally high (\>=120 msec), QT interval and corrected QT (QTcF; according to Fridericia's formula) interval (\>450 msec, \>480 msec, or \>500 msec, increases from baseline \>30 msec or \>60 msec.)
Percentage of Participants Who Progressed to Respiratory Failure (of Any Cause) Requiring Mechanical Ventilation (Invasive or Noninvasive) and/or Death Among Those Who Developed RSV LRTI or RSV-associated LRTC Per the EAC's Assessment Up to Day 49 Percentage of participants who progressed to respiratory failure (of any cause) requiring mechanical ventilation (invasive or noninvasive) and/or death among those who developed RSV LRTI or RSV-associated LRTC per the EAC's assessment was assessed. Here, '0' in the 'number of participants analyzed' field (N=0) signifies that no participants were available for the analysis because none of the participants developed RSV LRTI or RSV-associated LRTC per the EAC's Assessment.
Percentage of Participants With Treatment-emergent Abnormal Vital Signs Findings Up to Day 49 Percentage of participants with abnormal vital signs findings was assessed. Abnormal vital parameters included pulse rate: abnormally low \<=45 bpm, abnormally high \>=120 bpm; Systolic Blood Pressure (SBP): abnormally low \<=90 Millimeter of mercury (mmHg), Grade 1 (mild): \> 90 mmHg - \< 100 mmHg, Grade 2 (moderate): \>= 100 mmHg to \<110 mmHg, Grade 3 (severe): \>=110 mmHg; Diastolic BP: abnormally low \<=50 mmHg, Grade 1: \>90 mmHg to \<100 mmHg, Grade 2: \>=100 mmHg to \<110 mmHg, Grade 3: \>=110 mmHg; Respiratory rate- Grade 1 (mild): 17-20 breaths per minute, Grade 2 (moderate): 21-25 breaths per minute, Grade 3 (severe): \>25 breaths per minute, Grade 4 (potentially life threatening): intubation; Temperature: abnormally high \>38.0 degree celsius. Vital signs abnormalities reported for at least 1 participant were reported in this outcome measure. Treatment-emergent: any abnormality occurred post first dose of study drug up to EOS (that is, Day 49).
Percentage of Participants Who Progressed to Respiratory Failure (of Any Cause) Requiring Mechanical Ventilation (Invasive or Noninvasive) and/or Death (All-cause Mortality) Up to Day 49 Percentage of participants who progressed to respiratory failure (of any cause) requiring mechanical ventilation (invasive or noninvasive) and/or death (all-cause mortality) was assessed.
Percentage of Participants Who Progressed to Death (All-cause Mortality) Among Those Who Developed RSV LRTI or RSV-associated LRTC Per the EAC's Assessment Up to Day 49 Percentage of participants who progressed to death (all-cause mortality) among those who developed RSV LRTI or RSV-associated LRTC per the EAC's assessment was assessed. Here, '0' in the 'number of participants analyzed' field (N=0) signifies that no participants were available for the analysis because none of the participants developed RSV LRTI or RSV-associated LRTC per the EAC's Assessment.
Percentage of Participants Who Progressed to Death (All-cause Mortality) Up to Day 49 Percentage of participants who progressed to death (all-cause mortality) was assessed.
Percentage of Participants Who Progressed to Respiratory Failure (of Any Cause) Requiring Mechanical Ventilation (Invasive or Noninvasive) Among Those Who Developed RSV LRTI or RSV-associated LRTC Per the EAC's Assessment Up to Day 49 Percentage of participants who progressed to respiratory failure (of any cause) requiring mechanical ventilation (invasive or noninvasive) among those who developed RSV LRTI or RSV-associated LRTC per the EAC's assessment was assessed. Here, '0' in the 'number of participants analyzed' field (N=0) signifies that no participants were available for the analysis because none of the participants developed RSV LRTI or RSV-associated LRTC per the EAC's Assessment.
Percentage of Participants Who Progressed to Respiratory Failure (of Any Cause) Requiring Mechanical Ventilation (Invasive or Noninvasive) Up to Day 49 Percentage of participants who progressed to respiratory failure (of any cause) requiring mechanical ventilation (invasive or noninvasive) was assessed.
Number of Supplemental Oxygen Free Days Through Day 28 Number of supplemental oxygen free days was assessed. The number of supplemental oxygen free days was the number of days the participants did not receive/require supplemental oxygen during the first 28 days post treatment.
Percentage of Participants With Treatment-emergent Oxygen Supplementation Up to Day 49 Percentage of participants who required treatment-emergent oxygen supplementation (e.g., supplemental oxygen, noninvasive pressure ventilation, invasive mechanical ventilation \[tracheal tube, laryngeal mask or tracheostomy\]). Any AE which occurred post first dose administration of study drug up to the end of study (that is, Day 49) were considered as treatment-emergent.
Respiratory Rate Over Time Baseline (Day 1), Days 15, 28, and 35 Respiratory rate over time was reported by investigator. In this outcome measure, only those timepoints in which individual participant had data were reported.
Heart Rate Over Time Baseline (Day 1), Days 15, 28, and 35 Heart rate over time was reported by investigator. In this outcome measure, only those timepoints in which individual participant had data were reported.
Peripheral Capillary Oxygen Saturation (SpO2) Over Time Baseline (Day 1), Days 15, 28, and 35 Peripheral capillary oxygen saturation (SpO2) over time was reported by investigator. In this outcome measure, only those timepoints in which individual participant had data were reported.
Body Temperature Over Time Baseline (Day 1), Days 15, 28, and 35 Body temperature (in Degrees Celsius) over time was reported. In this outcome measure, only those timepoints in which individual participant had data were reported.
Percentage of Participants Hospitalized (of Participants Who Were Not Hospitalized at Baseline) Up to Day 49 Percentage of participants who were not hospitalized at baseline and required hospitalization during the study was assessed.
Percentage of Participants Who Were Re-hospitalized Up to Day 49 Percentage of participants who were re-hospitalized (of participants who were hospitalized at baseline and discharged during the study and of participants who were not hospitalized at baseline and required hospitalization and were discharged during the study) was assessed in this outcome measure.
Duration of Hospital Stay Up to Day 49 Duration (in days) of hospital stay was assessed.
Duration of Intensive Care Unit (ICU) Stay Up to Day 49 Duration of ICU stay was assessed. Duration (in hours) was defined as total number of hours a participant was in ICU from first dose of study drug until study termination.
Number of Participants With Grade 3 and Grade 4 Treatment-emergent Adverse Events (TEAEs) in the Infections and Infestations System Organ Class Up to Day 49 An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non investigational) product. An AE did not necessarily had a causal relationship with the intervention. Participants with Grade 3 or Grade 4 TEAE were assessed in this outcome measure. Any AE which occurred post first dose administration of study drug up to the end of study (that is, Day 49) were considered as treatment-emergent.
Number of Participants With Respiratory Related AEs Up to Day 49 Number of participants with respiratory related AEs (respiratory infections) was assessed.
Number of Participants With Thoracic-related AEs Up to Day 49 Number of participants with thoracic-related AEs was assessed.
Number of Participants With Antibiotic Use Among Those Who Developed RSV LRTI or RSV-Associated LRTC Per the EAC's Assessment Up to Day 49 Number of participants with antibiotic use among those who developed RSV LRTI or RSV-associated LRTC per the EAC's assessment was assessed. Here, '0' in the 'number of participants analyzed' field (N=0) signifies that no participants were available for the analysis because none of the participants developed RSV LRTI or RSV-associated LRTC per the EAC's Assessment.
Plasma Concentration of JNJ-53718678 Days 1, 3, 8, 15 and 22 Plasma Concentration of JNJ-53718678 was reported. In this outcome measure, only those timepoints in which individual participant had data were reported.
RSV Viral Load Over Time Baseline (Day 1), Days 15, 28, and 35 RSV viral load (RSV B) was measured over time by quantitative reverse transcription polymerase chain reaction (qRT-PCR) in the nasal swab specimens collected at the clinic visits and at home. In this outcome measure, only those timepoints in which individual participant had data were reported.
Trial Locations
- Locations (69)
Hosp. de La Santa Creu I Sant Pau
🇪🇸Barcelona, Spain
Hosp. Gral. Univ. Gregorio Maranon
🇪🇸Madrid, Spain
Hosp. Univ. 12 de Octubre
🇪🇸Madrid, Spain
Hosp Clinico Univ de Salamanca
🇪🇸Salamanca, Spain
Hosp. Univ. Marques de Valdecilla
🇪🇸Santander, Spain
Hosp. Virgen Del Rocio
🇪🇸Sevilla, Spain
Skanes universitetssjukhus
🇸🇪Malmö, Sweden
Kaohsiung Medical University Hospital
🇨🇳Kaohsiung, Taiwan
Ronald Reagan UCLA Medical Center
🇺🇸Los Angeles, California, United States
Hospital das Clinicas de Porto Alegre
🇧🇷Porto Alegre, Brazil
China Medical University Hospital
🇨🇳Taichung, Taiwan
National Cheng Kung University Hospital
🇨🇳Tainan, Taiwan
National Taiwan University Hospital
🇨🇳Taipei, Taiwan
Kings College Hospital NHS Trust
🇬🇧London, United Kingdom
Henry Ford Hospital - Hematology/oncology
🇺🇸Detroit, Michigan, United States
Northwell Health Cancer Institute
🇺🇸Lake Success, New York, United States
MD Anderson Cancer Center - University of Texas
🇺🇸Houston, Texas, United States
Hospital Espanol De Bahia Blanca
🇦🇷Bahia Blanca, Argentina
Hospital Italiano de La Plata
🇦🇷Ciudad De La Plata, Argentina
Sanatorio Allende
🇦🇷Cordoba, Argentina
Hospital Privado-Universitario de Cordoba
🇦🇷Cordoba, Argentina
Clinica Mayo de UMCB
🇦🇷San Miguel de Tucuman, Argentina
Peter MacCallum Cancer Centre
🇦🇺Melbourne, Australia
Royal Melbourne Hospital
🇦🇺Melbourne, Australia
Westmead Hospital
🇦🇺Westmead, Australia
AZ Sint-Jan
🇧🇪Brugge, Belgium
Jules Bordet Institute
🇧🇪Brussels, Belgium
UZ Brussel
🇧🇪Brussels, Belgium
UZ Gent
🇧🇪Gent, Belgium
UZ Leuven
🇧🇪Leuven, Belgium
CHU de Liege
🇧🇪Liege, Belgium
Jessa Ziekenhuis
🇧🇪Limburg, Belgium
Fundacao Pio XII
🇧🇷Barretos, Brazil
Universidade Federal De Minas Gerais - Hospital das ClÃnicas
🇧🇷Belo Horizonte, Brazil
Centro de Pesquisa e Ensino em Oncologia de Santa Catarina CEPEN
🇧🇷Florianopolis, Brazil
Universidade Federal do Ceara Hospital Universitario Walter Cantidio
🇧🇷Fortaleza, Brazil
Fundacao Doutor Amaral Carvalho
🇧🇷Jau, Brazil
Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto Hospital de Base
🇧🇷Sao Jose do Rio Preto, Brazil
Real e Benemerita Associacao Portuguesa de Beneficencia
🇧🇷Sao Paulo, Brazil
Fundacao Antonio Prudente A C Camargo Cancer Center
🇧🇷Sao Paulo, Brazil
Sociedade Beneficente de Senhoras - Hospital SÃrio Libanês
🇧🇷São Paulo, Brazil
UMHAT 'Sveti Georgi'-Plovdiv
🇧🇬Plovdiv, Bulgaria
Specialized Hospital for Active Treatment of Haematologic Diseases
🇧🇬Sofia, Bulgaria
Multiprofile Hospital for Active Treatment 'Sveta Marina' EAD
🇧🇬Varna, Bulgaria
Hôpital d'Instruction des Armées Percy
🇫🇷Clamart, France
Institut Universitaire du Cancer Toulouse - Oncopole
🇫🇷Toulouse, France
Rambam Medical Center
🇮🇱Haifa, Israel
Hadassah Medical Center
🇮🇱Jerusalem, Israel
Sheba Medical Center
🇮🇱Ramat Gan, Israel
Sourasky (Ichilov) Medical Center
🇮🇱Tel Aviv, Israel
Ospedale San Raffaele HSR Istituto Scientifico Universitario San Raffaele
🇮🇹Milano, Italy
Ematologia Fondazione Univ. Policlinico Gemelli Università Cattolica del Sacro Cuore
🇮🇹Roma, Italy
Akita University Hospital
🇯🇵Akita, Japan
Chiba University Hospital
🇯🇵Chiba, Japan
Tokai University Hospital
🇯🇵Isehara, Japan
Japanese Red Cross Society Nagano Hospital
🇯🇵Nagano, Japan
Okayama University Hospital
🇯🇵Okayama, Japan
The Catholic University of Korea Seoul St Mary s Hospital
🇰🇷Seoul, Korea, Republic of
Hospital Ampang
🇲🇾Ampang Jaya, Malaysia
Penang General Hospital
🇲🇾Georgetown, Malaysia
University Malaya Medical Centre
🇲🇾Kuala Lumpur, Malaysia
Sunway Medical Centre
🇲🇾Petaling Jaya, Malaysia
Leiden University Medical Center
🇳🇱Leiden, Netherlands
Hosp Univ Vall D Hebron
🇪🇸Barcelona, Spain
University Of Minnesota
🇺🇸Minneapolis, Minnesota, United States
Weill Cornell Medical College
🇺🇸New York, New York, United States
University Hospitals Cleveland Medical Center
🇺🇸Cleveland, Ohio, United States
Fox Chase Cancer Center
🇺🇸Philadelphia, Pennsylvania, United States
Baylor Scott and White Research Institute
🇺🇸Dallas, Texas, United States